Loading Live Market Data...
Technology

Science Corporation Secures $400 Million Funding Round at $3.5 Billion Valuation

TechCrunch•2 min read•Nov 17, 2026•Updated: 12h ago•REF: OPA-261117-P5U
Image Credits:Kimberly White/Getty Images for TechCrunch
Image Credits:Kimberly White/Getty Images for TechCrunch
Photo: Image Credits:Kimberly White/Getty Images for TechCrunch

Key Takeaways

  • Science Corporation raised a $400 million Series D funding round.
  • The new financing values the medical technology startup at $3.5 billion.
  • The company's flagship PRIMA chip restores vision for patients with age-related macular degeneration.
Listen to this story
AI Wire Voice•15 sections
Share Story

OPA WIRE, Nov 17 (OPA) — Science Corporation announced the $400 million Series D funding round in a blog post on November 17, 2026. A person familiar with the transaction confirmed the $3.5 billion valuation to TechCrunch. Investors in the round included Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.

Founded in 2021 by former Neuralink president Max Hodak, the startup focuses on technologies designed to interact with the human brain. Its primary commercial product is PRIMA, a wearable and implantable chip that assists patients suffering from age-related macular degeneration. The device is already approved in Europe, commercially available in Germany, and currently undergoing clinical trials for additional conditions.

Hodak announced at TechCrunch Disrupt that PRIMA is now being tested for Stargardt’s disease, another condition that causes blindness. The company plans to introduce the device to the United States using the Food and Drug Administration's Humanitarian Device Exemption. Science persuaded the FDA that advanced bilateral age-related macular degeneration qualifies as a rare condition eligible for the expedited regulatory pathway.

Beyond vision restoration, the startup's long-term objective involves connecting directly to the human brain via a bio-hybrid sensor combining cultured neurons and silicon. The company is designing initial human trials for this sensor in collaboration with Yale neurosurgery professor Murat Günel. Günel indicated the technology could eventually provide treatments for Parkinson's disease and other neurological injuries and illnesses.

Share Story
OPA Morning Intelligence

Subscribe to the Global Briefing

Receive our flagship executive dispatch every morning. Essential geopolitical analysis, financial benchmarks, and breaking world events delivered to your inbox.

MO

Mohammad Karamali

Verified Wire Contributor
OPA Global Newsroom & Wire Desk

Senior correspondent covering geopolitics, regional developments, and strategic international affairs for OPA News (Optimum Public Affairs).

This dispatch adheres to the OPA Editorial Code of Ethics, independent multi-source verification, and factual accuracy guidelines.View Author Dossier & Archive

Reader Discussion

Leave a Comment

0 Comments

Loading comments...

MK
Mohammad KaramaliStaff JournalistToronto, Canada

Owner

Editorial Oversight & Machine-Assisted Reporting

Human-in-the-Loop Verified

Editorial Oversight & Machine-Assisted Reporting: This dispatch was synthesized and localized via OPA automated intelligence under continuous human editorial supervision.

Wire Source

This report was synthesized from TechCrunch under journalistic fair use.